Cooper J F, Finkle W D
Prostate. 1980;1(4):441-50. doi: 10.1002/pros.2990010407.
Data are presented demonstrating that radioimmunoassay techniques for measurement of serum prostatic acid phosphatase are more sensitive than enzymatic methods in the detection of all stages of prostatic cancer. The possibility of using a solid phase RIA technique to screen for prostatic cancer is considered. Sixty-three hundred and twenty men over age 45 entering a clinical laboratory for any indication were evaluated using the RIA test for PAP. In this group 444 (7%) had elevated test values. Clinical recall and urologic review of the patients with elevated test results yielded 67 who were suspect for prostatic cancer, of whom 59 (88%) were confirmed by prostatic needle biopsy. These data suggest that the RIA for prostatic acid phosphatase as an isolated clinical procedure is not sufficiently specific to be used for screening due to the large number of false-positive results. However, the RIA-PAP test in combination with a follow-up urologic examination is quite specific and deserves further consideration as a screening method for prostatic malignancy.
所呈现的数据表明，在检测前列腺癌的各个阶段时，用于测量血清前列腺酸性磷酸酶的放射免疫测定技术比酶法更敏感。考虑了使用固相放射免疫测定技术筛查前列腺癌的可能性。对6320名45岁以上因任何指征进入临床实验室的男性使用放射免疫测定法检测前列腺酸性磷酸酶（PAP）进行评估。在该组中，444人（7%）检测值升高。对检测结果升高的患者进行临床召回和泌尿科复查，发现67人疑似前列腺癌，其中59人（88%）经前列腺穿刺活检确诊。这些数据表明，由于大量假阳性结果，单独将前列腺酸性磷酸酶放射免疫测定作为一种临床程序用于筛查时特异性不足。然而，放射免疫测定法检测前列腺酸性磷酸酶（RIA-PAP）结合后续泌尿科检查相当特异，作为前列腺恶性肿瘤的筛查方法值得进一步考虑。
